Fox Chase Cancer Center News

CHICAGO, IL (June 2, 2012)––A new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who no longer respond to crizotinib—the only approved ALK inhibitor.  Results of this Novartis-sponsored sudy will be presented by a researcher from Fox Chase Cancer Center during the 2012 Annual Meeting of the American Society of Clinical Oncology on Sunday, June 3.  

CHICAGO, IL (June 2, 2012)––Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting drug lapatinib can slow the spread of cancer cells in individuals with advanced breast cancer who have already tried other chemotherapy medications.

CHICAGO, IL (June 2, 2012)––More than one-fifth of people who have received referrals to test for cancer-causing genes say they will only undergo testing if their insurance covers the cost—just as more insurers are instituting cost-sharing for medical services like genetic testing, according to new findings from Fox Chase Cancer Center in Philadelphia released at this year's 2012 Annual Meeting of the American Society of Clinical Oncology on Saturday, June 2.

CHICAGO, IL (June 2, 2012)––For some patients with muscle-invasive bladder cancer, treatment may begin before they undergo cystectomy, or surgical removal of the bladder. They may be advised by oncologists to receive chemotherapy before surgery. A large randomized clinical trial published in 2003 demonstrated a survival benefit for neoadjuvant, or pre-surgical, MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) using a standard dose and schedule. However, in an effort to improve toxicity, standard MVAC has been essentially abandoned in favor of other regimens.

CHICAGO, IL (June 2, 2012)––Each year, through its Special Awards Program, the American Society of Clinical Oncology (ASCO) recognizes researchers, patient advocates, and leaders of the global oncology community who, through their work, have made significant contributions to enhancing cancer care. These recipients of ASCO’s highest, most prestigious awards collectively represent significant strides in cancer treatment and leadership in the oncology community. This year, one of the Special Awards honorees is retired Fox Chase Cancer Center faculty member Robert F.

CHICAGO, IL (June 2, 2012)–If racial and ethnic disparities in breast cancer exist, they are not due to differences in the use of imaging to assess the extent of tumors before surgery, according to new findings that will be presented by Fox Chase Cancer Center researchers at the 2012 Annual Meeting of the American Society of Clinical Oncology on Monday, June 4.

CHICAGO, IL (June 2, 2012)––Nearly half of the research presented at ASCO’s annual meeting last year came from researchers with ties to companies, and the amount appears to be increasing every year, according to new findings from Fox Chase Cancer Center. The new findings will be presented this year at the 2012 American Society of Clinical Oncology Annual Meeting on Monday, June 4.

PHILADELPHIA (May 10, 2012)—Fox Chase Cancer Center physicians have, once again, made a strong showing in Philadelphia magazine’s annual "Top Doctors" issue — now available on newsstands — with 31 clinicians listed among the region’s best in their specialties by a national survey of professional peers.  The list of “Top Doctors” serves as an important standard for anyone seeking expert medical care in the Philadelphia area.